Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK042 in malignant ascites from gynecologic cancer
NCT06415500Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK042 in malignant ascites, sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-limiting Toxicity at 28 days. Planned start May 2024; status: not yet recruiting.
02
Drugs
NK042
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT06415500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415500.